Excelimmune Adds $12M to Advance Polyclonal Antibodies

Arlene Weintraub12/20/11Follow @awjourn

Share and Comment

Leave a Comment Order a Reprint E-mail this Story

• Share on Twitter
• Share on Facebook


• Share on Linkedin
• Share on Google

Woburn, MA-based Excelimmune announced today that it has raised $12 million from an undisclosed “private” investor. The funding follows close on the heels of a $10.5 million Series B round the company announced in May.

Excelimmune is developing “polyclonal” antibodies, which are therapeutic proteins designed to bind to multiple regions of specific disease-causing antigens. The company says the proceeds from the financing will be used to develop its molecules aimed at combating infectious diseases, including a polyclonal antibody it is developing to fight Staphylococcus aureus (MRSA).

Excellimune was co-founded in 2006 by Vincent Coljee, who originally pioneered human polyclonal antibody technology at Symphogen AS, a Danish biotech company.

Arlene Weintraub is the east coast biotechnology editor and editor of Xconomy New York. She can be reached at aweintraub@xconomy.com. Follow @awjourn